Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFirst Affiliated Hospital of Ningbo University
About this trial
The goal of this observational study is to learn whether red dichromatic imaging (RDI) can help doctors see the bronchoscopic field more clearly after a biopsy. The study will include adults who need a bronchoscopic biopsy because doctors can see an abnormal area inside the airway.During a bronchoscopic biopsy, bleeding can happen after tissue is taken. Blood may cover the biopsy area and make it harder for doctors to see where to continue the procedure.
RDI is an imaging mode that uses special colors of light to help show blood-covered areas more clearly.The main question this study aims to answer is:Does RDI improve visibility of the bronchoscopic field after bleeding caused by bronchoscopic biopsy? Researchers will compare images taken with standard white light imaging and RDI during the same bronchoscopy procedure. Both types of images will be taken after the first biopsy and before any field-clearing treatment is done.
Participants will have bronchoscopic biopsy as part of their regular medical care, have images taken using standard white light imaging and RDI during the same procedure, have routine follow-up for possible medical problems after bronchoscopy. Taking part in this study will not add extra biopsies or change the participant's regular medical care.
Eligibility criteria
Qualifiers
Age ≥18 years.
Visible abnormal endobronchial lesion under bronchoscopy, including endobronchial neoplasm, mucosal abnormality, airway stenosis, or other lesion requiring biopsy to determine its nature.
Provision of informed consent to participate in this clinical study and signing of the informed consent form.
Disqualifiers
Presence of contraindications to bronchoscopy, such as severe cardiopulmonary disease, coagulation dysfunction (including patients receiving anticoagulant therapy and/or anticoagulant drugs who have not discontinued these drugs for more than 5 days before the examination), poor tolerance of anesthesia, psychiatric disease, or severe neurosis.
Intra-procedural decrease in SpO₂ or inability to tolerate bronchoscopy.
Obvious airway bleeding observed during bronchoscopy that may increase the risk of worsening the patient's condition.
Images that are obviously blurred or out of focus, or that contain severe reflection, bubbles, or instrument obstruction, making subsequent image analysis impossible.
Trial design
Treatments tested in this trial
- Red Dichromatic Imaging (RDI)
Treatment groups
No treatment groups listed
Sponsors and collaborators
First Affiliated Hospital of Ningbo University
Lead sponsor
Shanghai Chest Hospital
Collaborator
Anhui Chest Hospital
Collaborator
Huzhou Central Hospital
Collaborator
The Second Affiliated Hospital of Jiaxing University
Collaborator
Lanxi Hospital of Traditional Chinese Medicine
Collaborator
Zhoushan Hospital of Zhejiang
Collaborator
Source ClinicalTrials.gov